Evidence map›Paper›PMID 40266523›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Biomimetic Glyconanoparticle Nanoghost Vaccine Based on Red Blood Cells.

Nofar Israel, Shani Leviatan Ben-Arye, Andrea Perota, Cesare Galli, Vered Padler-Karavani

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nofar IsraelDepartment of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Shani Leviatan Ben-AryeDepartment of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Andrea PerotaAvantea Srl, Cremona, Italy.
Cesare GalliAvantea Srl, Cremona, Italy.
Vered Padler-KaravaniDepartment of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. vkaravani@tauex.tau.ac.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer vaccine is an active immunotherapy approach that aims to stimulate the host's immune responses toward specific targets on cancer cells, to direct their killing. Cancer cells commonly express aberrant cell surface glycosylation that support their immune evasion. Therefore, cancer glycosylation could be used as an efficient target for therapy. Lipid-based glyconanoparticles that express cancer glycosylation could mimic cancer cells and be used as therapeutic cancer vaccines. Here, we describe generation of biomimetic glyconanoparticles cancer vaccine based on porcine red blood cells that express cancer glycosylation containing the dietary nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc).

Indexed as

Biomimetic MaterialsBiomimeticsCancer VaccinesErythrocytesNanoparticlesAnimalsGlycosylationHumansNeuraminic AcidsSwineCancer VaccinesNeuraminic AcidsN-glycolylneuraminic acidBiomimeticCancer vaccineGlycan microarrayGlyconanoparticleN-glycolylneuraminic acid (Neu5Gc)Sialic acid

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.